POXEL |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.654 EUR | +6.34% |
|
-0.76% | +18.69% |
| Apr. 11 | Poxel: CDC falls below the 10% threshold | CF |
| Feb. 15 | Poxel S.A. Reports Unaudited Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
Presentation Operator MessageOperator (Operator)This meeting is being [Audio Gap] ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Poxel is a biopharmaceutical company specializing in developing innovative treatments for metabolic diseases, including non-alcoholic steatohepatitis (NASH) and rare diseases.
TWYMEEG® (Imeglimine), Poxel's lead product and the first in its class of medicines, which targets mitochondrial dysfunction, has been marketed in Japan for the treatment of type 2 diabetes.
For the treatment of NASH, the PXL065 met its primary endpoint in a streamlined Phase II trial, and PXL770 has completed a Phase IIa proof-of-concept study by reaching its objectives. In adrenoleukodystrophy (ALD), a rare inherited metabolic disease, the company intends to initiate Phase IIa proof-of-concept studies with the PXL065 and the PXL770 in patients with adrenomyeloneuropathy (AMN).
Calendar
2024-05-15
- Q1 2024 Sales and Revenue Release
| 1st Jan change | Capi. | |
|---|---|---|
| +18.69% | 27.02M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -0.44% | 21.66B | |
| -18.35% | 20.77B | |
| -7.45% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- POXEL Stock
- News Poxel
- Transcript : Poxel S.A., 2021 Earnings Call, Mar 22, 2022
